JP2016534034A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534034A5 JP2016534034A5 JP2016519871A JP2016519871A JP2016534034A5 JP 2016534034 A5 JP2016534034 A5 JP 2016534034A5 JP 2016519871 A JP2016519871 A JP 2016519871A JP 2016519871 A JP2016519871 A JP 2016519871A JP 2016534034 A5 JP2016534034 A5 JP 2016534034A5
- Authority
- JP
- Japan
- Prior art keywords
- pcv2
- polypeptide
- infection
- sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001673669 Porcine circovirus 2 Species 0.000 claims 30
- 229920001184 polypeptide Polymers 0.000 claims 23
- 101700047669 ORF2 Proteins 0.000 claims 14
- 101710042748 UL80 Proteins 0.000 claims 14
- 101700020292 V2 Proteins 0.000 claims 14
- 201000009910 diseases by infectious agent Diseases 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 235000001014 amino acid Nutrition 0.000 claims 10
- 230000002163 immunogen Effects 0.000 claims 10
- 230000035772 mutation Effects 0.000 claims 9
- 229920000023 polynucleotide Polymers 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 241000701447 unidentified baculovirus Species 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 210000004072 Lung Anatomy 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000038129 antigens Human genes 0.000 claims 2
- 108091007172 antigens Proteins 0.000 claims 2
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 208000003322 Coinfection Diseases 0.000 claims 1
- 210000003563 Lymphoid Tissue Anatomy 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 206010039101 Rhinorrhoea Diseases 0.000 claims 1
- 206010058874 Viraemia Diseases 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 235000021053 average weight gain Nutrition 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 230000003247 decreasing Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000000012 isoleucine group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- 125000001235 proline group Chemical group [H]N1[C@@](C(=O)[*])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
Claims (25)
- 下記(a)、(b)及び(c)から成る群から選択されるポリペプチド:
(a)PCV2 ORF2タンパク質であって、
−アミノ酸59位にアルギニン残基又はリジン残基、及び/又は
−アミノ酸88位にプロリン残基、及び/又は
−アミノ酸151位にスレオニン残基、及び/又は
−アミノ酸206位にイソロイシン残基、及び/又は
−アミノ酸232位にアスパラギン残基を有し、
かつアミノ酸63位にアルギニン残基又はリジン残基以外のアミノ酸を有し、
該アミノ酸の位置の番号付けが野生型PCV2 ORF2タンパク質のアミノ酸配列に対応する、前記PCV2 ORF2タンパク質;
(b)(i)BCループに少なくとも1つの変異を含むこと、及び(ii)そのような変異を含まないPCV2 ORF2タンパク質と比較してより大量に発現されることを特徴とするPCV2 ORF2タンパク質;
(c)(a)及び(b)の組合せ。 - (b)でBCループに少なくとも1つの変異を含むPCV2 ORF2タンパク質が、そのような変異を含まないPCV2 ORF2タンパク質と比較して、少なくとも2倍大量に発現され、及び/又はBCループに少なくとも1つの変異を含む前記PCV2 ORF2タンパク質が、そのような変異を含まない前記PCV2 ORF2タンパク質と比較して、バキュロウイルス発現系でより大量に発現され、及び/又はそのような変異を含まない前記PCV2 ORF2タンパク質が野生型PCV2 ORF2タンパク質である、請求項1に記載のポリペプチド。
- (b)でBCループのすくなくとも1つの変異がアミノ酸58から66位の領域における少なくとも1つの変異であり、該アミノ酸の位置の番号付けが野生型PCV2 ORF2タンパク質のアミノ酸配列に対応する、請求項1または2に記載のポリペプチド。
- PCV2 bサブタイプ(PCV2b)ORF2タンパク質である、請求項1から3のいずれか1項に記載のポリペプチド。
- 配列番号:1のアミノ酸配列と少なくとも90%の配列同一性を有するアミノ酸配列を含むか又は前記配列から成るPCV2 ORF2タンパク質である、請求項1から4のいずれか1項に記載のポリペプチド。
- 配列番号:6−9に示される配列から成る群から選択される配列、及び/又は配列番号:10−45から成る群から選択される配列を含む、請求項1から5のいずれか1項に記載のポリペプチド。
- 野生型PCV2 ORF2タンパク質が配列番号:2に示されるタンパク質である、請求項1から6のいずれか1項に記載のポリペプチド。
- 請求項1から7のいずれか1項に記載のポリペプチドを含む免疫原性組成物。
- 請求項1から7のいずれか1項に記載のポリペプチドをコードする配列を含む、ポリヌクレオチド。
- 請求項1から7のいずれか1項に記載のポリペプチドをコードする配列を含むポリヌクレオチドを含む、プラスミド。
- 請求項1から7のいずれか1項に記載のポリペプチドをコードする配列を含むポリヌクレオチドを含むプラスミドを含む、細胞。
- 複数の、請求項1から7のいずれか1項に記載のポリペプチドを含む、ウイルス様粒子。
- 請求項1から7のいずれか1項に記載のポリペプチドをコードする配列を含むポリヌクレオチドを含む、バキュロウイルス。
- 請求項1から7のいずれか1項に記載のポリペプチドをコードする配列を含むポリヌクレオチドを含むバキュロウイルスを含む、細胞。
- −請求項1から7のいずれか1項に記載のポリペプチド、
−請求項8に記載の免疫原性組成物、
−請求項9に記載のポリヌクレオチド、
−請求項12に記載のウイルス様粒子、
−請求項13に記載のバキュロウイルス、
−請求項10に記載のプラスミド、及び/又は
−請求項11又は14に記載の細胞、の
医薬の調製のための使用。 - PCV2感染の治療若しくは予防、PCV2感染により引き起こされる臨床徴候の軽減、予防若しくは治療、又はPCV2感染により引き起こされる疾患の予防若しくは治療のための請求項8に記載の免疫原性組成物。
- PCV2感染が、PCV2 bサブタイプ(PCV2b)及び/又はbサブタイプ以外のサブタイプのPCV2による感染である、請求項16に記載の免疫原性組成物。
- PCV2感染が、(i)PCV2b及び(ii)bサブタイプ以外のサブタイプのPCV2による同時感染である、請求項17に記載の免疫原性組成物。
- bサブタイプ以外のサブタイプのPCV2感染が、PCV2 aサブタイプ(PCV2a)及び/又はPCV2 cサブタイプ(PCV2c)による感染である、請求項17に記載の免疫原性組成物。
- PCV2bによる感染が、配列番号:2の配列と少なくとも94%同一であるポリペプチドを含むか、又は配列番号:2の配列と少なくとも94%同一であるポリペプチドをコードする配列を含むポリヌクレオチドを含むPCV2による感染である、請求項17に記載の免疫原性組成物。
- PCV2aによる感染が、配列番号:3の配列と少なくとも94%同一であるポリペプチドを含むか、又は配列番号:3の配列と少なくとも94%同一であるポリペプチドをコードする配列を含むポリヌクレオチドを含むPCV2による感染である、請求項19に記載の免疫原性組成物。
- PCV2感染の治療又は予防がPCV2に対する免疫応答の誘発に基づくか又は前記免疫応答の誘発を含むか又は前記免疫応答の誘発から成り、前記臨床徴候が、リンパ系枯渇、リンパ系炎症、リンパ系組織におけるPCV2抗原IHC陽性、ウイルス血症、鼻汁排出、発熱、1日当たりの平均体重増加の低下、肺の炎症、肺組織におけるPCV2抗原IHC陽性から成る群から選択され、又は前記疾患がPMWSである、請求項16〜21のいずれか1項に記載の免疫原性組成物。
- 1回だけ投与するための、請求項16〜22のいずれか1項に記載の免疫原性組成物。
- 請求項10に記載のプラスミドを細胞にトランスフェクトする工程を含む、請求項1から7のいずれか1項に記載のポリペプチドを製造する方法。
- 請求項13に記載のバキュロウイルスを細胞に感染させる工程を含む、請求項1から7のいずれか1項に記載のポリペプチドを製造する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361885871P | 2013-10-02 | 2013-10-02 | |
US61/885,871 | 2013-10-02 | ||
PCT/US2014/058793 WO2015051099A1 (en) | 2013-10-02 | 2014-10-02 | Pcv2 orf2 protein variant and virus like particles composed thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016534034A JP2016534034A (ja) | 2016-11-04 |
JP2016534034A5 true JP2016534034A5 (ja) | 2017-11-09 |
JP6778104B2 JP6778104B2 (ja) | 2020-10-28 |
Family
ID=51795768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016519871A Active JP6778104B2 (ja) | 2013-10-02 | 2014-10-02 | Pcv2 orf2タンパク質変種および前記を含むウイルス様粒子 |
Country Status (12)
Country | Link |
---|---|
US (5) | US9505808B2 (ja) |
EP (1) | EP3052516B1 (ja) |
JP (1) | JP6778104B2 (ja) |
KR (2) | KR102409183B1 (ja) |
CN (1) | CN105658660A (ja) |
AU (1) | AU2014329524B2 (ja) |
CA (1) | CA2924228C (ja) |
DK (1) | DK3052516T3 (ja) |
EA (1) | EA035265B1 (ja) |
ES (1) | ES2778425T3 (ja) |
MX (1) | MX2016004063A (ja) |
WO (1) | WO2015051099A1 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA95602C2 (ru) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Иммуногенная композиция цвс2 и способы приготовления такой композиции |
WO2007094893A2 (en) | 2005-12-29 | 2007-08-23 | Boehringer Ingelheim Vetmedica, Inc. | Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs |
RU2488407C2 (ru) | 2005-12-29 | 2013-07-27 | Берингер Ингельхайм Ветмедика, Инк. | Поливалентные иммуногенные композиции pcv2 и способы получения таких композиций |
US20100129397A1 (en) | 2006-12-11 | 2010-05-27 | Boehringer Ingelheim Vetmedica, Inc. | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
EP1941903A1 (en) | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
EP1958644A1 (en) | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
CA2712006A1 (en) | 2008-01-23 | 2009-10-15 | Boehringer Ingelheim Vetmedica, Inc. | Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions |
CN105658660A (zh) * | 2013-10-02 | 2016-06-08 | 勃林格殷格翰动物保健公司 | Pcv2 orf2蛋白变体和由其组成的病毒样颗粒 |
US10555994B2 (en) | 2015-03-30 | 2020-02-11 | Boehringer Ingelheim Animal Health USA Inc. | PCV2 ORF2 carrier platform |
US9944904B2 (en) * | 2015-05-14 | 2018-04-17 | Merial Inc. | Method for porcine circovirus production and PCV2 vaccines |
CN104984335A (zh) * | 2015-07-14 | 2015-10-21 | 浙江诺倍威生物技术有限公司 | 猪圆环病毒双亚型orf2共表达载体构建及疫苗制备 |
JP2019507784A (ja) * | 2016-03-07 | 2019-03-22 | ヴァージニア テック インテレクチュアル プロパティーズ,インコーポレーテッド | キメラブタサーコウイルス2型(pcv2)ワクチン |
US10431889B2 (en) * | 2016-04-22 | 2019-10-01 | The Charles Stark Draper Laboratory, Inc. | Low-loss compact transmit impedance matching tuning technique |
CN106399350B (zh) * | 2016-09-07 | 2020-02-21 | 复旦大学 | 一种猪圆环病毒ii型病毒样颗粒疫苗及其制备方法 |
CN106399138B (zh) * | 2016-09-07 | 2019-11-12 | 复旦大学 | 猪圆环病毒ii型口服病毒样颗粒疫苗及其制备方法和应用 |
KR102669319B1 (ko) * | 2016-11-03 | 2024-05-28 | 베링거잉겔하임베트메디카게엠베하 | 돼지 파보바이러스에 대한 백신 |
CN106834241B (zh) * | 2017-03-02 | 2021-01-19 | 扬州大学 | 嵌合型猪圆环病毒活疫苗c1-402株及其构建方法 |
CN106834242B (zh) * | 2017-03-02 | 2021-02-23 | 扬州大学 | 嵌合型猪圆环病毒活疫苗c1-233株及其构建方法 |
CN107245477B (zh) * | 2017-06-06 | 2020-06-30 | 广东海大畜牧兽医研究院有限公司 | 一种猪圆环病毒2型病毒样颗粒的制备方法及通过该方法获得的病毒样颗粒 |
PL3697804T3 (pl) * | 2017-10-17 | 2024-01-03 | Intervet International B.V. | Rekombinowana ekspresja białka orf2 pcv2b w komórkach owadzich |
CN108484725A (zh) * | 2018-03-16 | 2018-09-04 | 广东海大畜牧兽医研究院有限公司 | 一种区分检测pcv2野毒抗体与疫苗抗体的多肽及其在elisa检测试剂盒中的应用 |
CN110358742B (zh) * | 2019-07-05 | 2020-12-22 | 武汉科前生物股份有限公司 | 猪圆环病毒2b型和2d型的二价亚单位疫苗及其制备方法 |
CN111415356B (zh) * | 2020-03-17 | 2020-12-29 | 推想医疗科技股份有限公司 | 肺炎征象的分割方法、装置、介质及电子设备 |
CN112010949B (zh) * | 2020-08-03 | 2021-07-27 | 山东绿都生物科技有限公司 | 一种重组pcv2病毒样颗粒蜂胶疫苗及其制备方法 |
CN114250259B (zh) * | 2020-09-21 | 2024-07-19 | 成都史纪生物制药有限公司 | 一种猪圆环2型病毒Cap蛋白病毒样颗粒的发酵培养基 |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
DE3875762T2 (de) | 1987-03-17 | 1993-05-13 | Akzo Nv | Adjuvanzienmischung. |
US5069901A (en) | 1988-02-03 | 1991-12-03 | Jones Elaine V | Preparation of a recombinant subunit vaccine against pseudorabies infection |
AU638970B2 (en) | 1989-01-23 | 1993-07-15 | Auspharm International Limited | Vaccine composition |
US5155037A (en) | 1989-08-04 | 1992-10-13 | The Texas A&M University System | Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems |
US5202430A (en) | 1990-01-16 | 1993-04-13 | University Of Tennessee | Transmissible gastroenteritis virus genes |
WO1991018627A1 (en) | 1990-05-29 | 1991-12-12 | Smithkline Beecham Corporation | Swine pneumonia vaccine and method for the preparation thereof |
US5565205A (en) | 1990-08-16 | 1996-10-15 | Solvay Animal Health, Inc. | Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof |
GB9023111D0 (en) | 1990-10-24 | 1990-12-05 | Wellcome Found | Expression system |
DK0555366T3 (da) | 1990-11-01 | 2000-08-28 | Univ Iowa State Res Found Inc | Fremgangsmåde til bakteriel svækkelse og vaccine |
US6042830A (en) | 1992-08-05 | 2000-03-28 | Boehringer Ingelheim Vetmedica, Inc. | Viral agent associated with mystery swine disease |
CA2076744C (en) | 1991-08-26 | 2000-06-27 | Danny W. Chladek | Viral agent associated with mystery swine disease |
US5580557A (en) | 1991-10-09 | 1996-12-03 | Iowa State University Research Foundation, Inc. | Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals |
US5338543A (en) | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
BR9507717A (pt) | 1994-05-10 | 1997-09-23 | American Home Prod | Vacina brsv viva modificada aperfeiçoada |
US5885823A (en) | 1995-06-05 | 1999-03-23 | Nobl Laboratories, Inc. | Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents |
WO1998006855A1 (en) | 1996-08-16 | 1998-02-19 | The Texas A & M University System | Compositions and methods for delivery of nucleic acids to hepatocytes |
DK0835930T3 (da) | 1996-10-09 | 2001-06-18 | Akzo Nobel Nv | Europæiske vaccinestammer af porcint reproduktions- og respirationssyndrom-virus. (PRRSV) |
UA78180C2 (uk) | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
US20060029617A1 (en) | 1997-10-03 | 2006-02-09 | Charreyre Catherine E | Porcine circovirus and Helicobacter combination vaccines and methods of use |
US7192594B2 (en) | 1997-10-03 | 2007-03-20 | Merial Limited | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
FR2781159B1 (fr) | 1998-07-06 | 2000-10-06 | Merial Sas | Vaccin circovirus et parvovirus porcin |
US6391314B1 (en) | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
US7211379B2 (en) | 1997-10-03 | 2007-05-01 | Merial Sas | Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2 |
US20040062775A1 (en) | 1997-12-05 | 2004-04-01 | Agence Francaise De Securite Sanitaire Des Aliments | Circovirus sequences associated with piglet weight loss disease (PWD) |
FR2772047B1 (fr) | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
PT2363488E (pt) | 1997-12-11 | 2015-01-13 | Univ Belfast | Síndrome multi-sistémica do definhamento pós-desmame de porcos |
WO1999045956A1 (en) | 1998-03-13 | 1999-09-16 | University Of Georgia Research Foundation, Inc. | Vaccines against circovirus infections |
EP0953574A1 (en) | 1998-04-30 | 1999-11-03 | Innogenetics N.V. | Immunodiagnostic reagent for the detection of Maedi-Visna virus and CAEV infection |
US6294176B1 (en) | 1998-07-10 | 2001-09-25 | Schering-Plough Veterinary Corp. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
US6472193B1 (en) | 1998-11-19 | 2002-10-29 | Azwell Inc. | Recombinant lysophosphatidic acid phosphatase |
FR2789695B1 (fr) | 1999-02-11 | 2003-03-07 | Merial Sas | Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs |
US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
US6943152B1 (en) | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
WO2001017556A1 (fr) | 1999-09-07 | 2001-03-15 | Shionogi & Co., Ltd. | Préparations vaccinales administrables par les muqueuses |
US6656478B1 (en) | 1999-11-12 | 2003-12-02 | Samuel D. Charles | Cross-protective salmonella vaccines |
EP1248646B1 (en) | 1999-12-21 | 2008-02-13 | Merial | Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another enteric pathogen |
US6808900B2 (en) | 2000-06-15 | 2004-10-26 | Manitoba, University Of | Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof |
WO2001096377A2 (en) | 2000-06-15 | 2001-12-20 | Purdue Research Foundation | Vaccine for congenital tremors in pigs |
US7018638B2 (en) | 2000-12-19 | 2006-03-28 | Wyeth | Mycoplasma hyopneumoniae bacterin vaccine |
MY129765A (en) | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
JP2002247979A (ja) | 2001-02-23 | 2002-09-03 | Nippon Biologicals Inc | マレック病ワクチンおよびその製造方法 |
EP1379671B1 (en) | 2001-03-27 | 2009-05-06 | University of Saskatchewan | Methods to culture circovirus |
US20030096377A1 (en) | 2001-06-28 | 2003-05-22 | Virginia Tech Intellectual Properties, Inc. | Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2 |
JP2005515162A (ja) | 2001-07-02 | 2005-05-26 | ファイザー・プロダクツ・インク | マイコプラズマ・ハイオニューモニエ(Mycoplasmahyopneumoniae)を用いた単回ワクチン接種 |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
US7276353B2 (en) | 2001-12-12 | 2007-10-02 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
US7279166B2 (en) | 2001-12-12 | 2007-10-09 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
US6841364B2 (en) | 2002-01-22 | 2005-01-11 | Protatek International, Inc. | Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof |
US20040121465A1 (en) | 2002-02-14 | 2004-06-24 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
US20030199581A1 (en) | 2002-03-13 | 2003-10-23 | Seligson Allen L. | Boswellin compositions enhanced with 3-beta-acetyl-11-keto-beta-boswellic acid ("AKBA") industrial manufacture and uses |
US20030215455A1 (en) | 2002-05-14 | 2003-11-20 | Bailey Reynolds | Vaccine stabilizer and method of use |
AU2002951692A0 (en) | 2002-09-23 | 2002-10-17 | Vital Biotech (Hong Kong) Limited | Improvements in or relating to vaccines |
WO2004069184A2 (en) | 2003-02-03 | 2004-08-19 | Cerebus Biologicals, Inc. | Methods for treating, preventing and detecting helicobacter infection |
US7563449B2 (en) | 2003-04-21 | 2009-07-21 | Pfizer Inc, | Methods for reducing cattle reproductive diseases |
CN1458167A (zh) | 2003-06-02 | 2003-11-26 | 中国农业科学院哈尔滨兽医研究所 | 截短表达的猪圆环病毒ⅱ型衣壳蛋白抗原及其应用 |
US7335361B2 (en) | 2003-06-09 | 2008-02-26 | Animal Technology Institute Taiwan | Fusion antigen used as vaccine |
CA2533581C (en) | 2003-07-24 | 2012-05-08 | Merial Limited | Vaccine formulations comprising an oil-in-water emulsion |
PT1651260E (pt) | 2003-07-25 | 2009-09-24 | Boehringer Ingelheim Vetmed | Lawsonia intracellularis de origem europeia e vacinas, agentes de diagnóstico e métodos para sua utilização |
FR2861731B1 (fr) | 2003-10-30 | 2006-02-24 | Centre Nat Rech Scient | Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations |
WO2005112995A1 (en) | 2004-04-26 | 2005-12-01 | Choongang Vaccine Laboratory Co., Ltd. | Inactivated mixed vaccine for porcine respiratory disease and the method of manufacturing thereof |
CN1579553A (zh) | 2004-05-18 | 2005-02-16 | 浙江大学 | Ii型猪圆环病毒核酸疫苗的制备方法及其应用 |
EP1778283A2 (en) | 2004-06-30 | 2007-05-02 | ID Biomedical Corporation of Quebec | Vaccine compositions for treating coronavirus infection |
US7833707B2 (en) | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
US7700285B1 (en) | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
RU2007130801A (ru) | 2005-01-13 | 2009-02-20 | Берингер Ингельхайм Ветмедика Гмбх (De) | Улучшенные вакцины против репродуктивно-респираторного синдрома свиней (prrs) |
US7300785B2 (en) | 2005-02-03 | 2007-11-27 | Universiteit Ghent | Culturing circular ssDNA viruses for the production of vaccines |
US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
JP5408998B2 (ja) | 2005-04-13 | 2014-02-05 | メリアル リミテッド | ブタサーコウイルス産生アッセイ |
US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
UA95458C2 (ru) | 2005-09-09 | 2011-08-10 | Интервет Интернешонал Б.В. | Вакцина против pcv-2 у mda-положительных поросят |
RU2488407C2 (ru) | 2005-12-29 | 2013-07-27 | Берингер Ингельхайм Ветмедика, Инк. | Поливалентные иммуногенные композиции pcv2 и способы получения таких композиций |
WO2007094893A2 (en) | 2005-12-29 | 2007-08-23 | Boehringer Ingelheim Vetmedica, Inc. | Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs |
EP2099927A4 (en) | 2006-11-22 | 2010-05-05 | Boehringer Ingelheim Vetmed | METHODS FOR REDUCING FLAMBEES OF DISEASES ASSOCIATED WITH PORCINIC CIRCOVIRUS |
US20100129397A1 (en) | 2006-12-11 | 2010-05-27 | Boehringer Ingelheim Vetmedica, Inc. | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
PL2094872T5 (pl) | 2006-12-15 | 2020-10-05 | Boehringer Ingelheim Animal Health USA Inc. | Leczenie świń seropozytywnych wobec przeciwciała anty-pcv2 antygenem pcv2 |
EP1941903A1 (en) | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
EP1958644A1 (en) | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
GB0712160D0 (en) * | 2007-06-22 | 2007-08-01 | Univ Ghent | Methods and compositions in the treatment of procine circoviral infection |
US20090017064A1 (en) | 2007-07-10 | 2009-01-15 | Wyeth | Methods and Compositions for Immunizing Pigs Against Porcine Circovirus |
US7829274B2 (en) | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
RU2493254C9 (ru) | 2007-12-21 | 2013-12-20 | ВАЙЕТ ЭлЭлСи | Способы и композиции для иммунизации свиней против свиного цирковируса |
CA2712006A1 (en) | 2008-01-23 | 2009-10-15 | Boehringer Ingelheim Vetmedica, Inc. | Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions |
EP2254595A4 (en) | 2008-02-15 | 2012-12-05 | Boehringer Ingelheim Vetmed | METHODS AND COMPOSITIONS FOR REDUCING THE IMPACT OF ENTERIC DISEASES |
US8444989B1 (en) | 2008-04-18 | 2013-05-21 | Boehringer Ingelheim Vetmedica Gmbh | One dose vaccination against mycoplasma infections of pigs |
TWI627281B (zh) | 2009-09-02 | 2018-06-21 | 百靈佳殷格翰家畜藥品公司 | 降低pcv-2組合物殺病毒活性之方法及具有改良免疫原性之pcv-2組合物 |
PT2547770T (pt) | 2010-03-16 | 2020-03-04 | Virginia Tech Intellectual Properties Inc | Vacina contra circovirus suíno, quimérica, atenuada, viva |
BR112012026599B1 (pt) | 2010-04-22 | 2020-11-24 | Koninklijke Philips N.V. | detector de contato com a pele e aparelho de cuidado pessoal |
US9932372B2 (en) | 2010-07-08 | 2018-04-03 | United Biomedical, Inc. | Designer peptide-based PCV2 vaccine |
WO2012033911A2 (en) | 2010-09-08 | 2012-03-15 | The Johns Hopkins University | Polyionic papilloma virus-like particle (vlp) vaccines |
EP2564869A1 (en) | 2011-09-02 | 2013-03-06 | Ceva Sante Animale | Synthetic capsid proteins and uses thereof |
CN103122352B (zh) | 2012-09-27 | 2015-02-11 | 华中农业大学 | 一种猪圆环病毒2型重组杆状病毒及制备方法和应用 |
CN105026419B (zh) * | 2013-03-01 | 2021-08-24 | 勃林格殷格翰动物保健美国有限公司 | 疫苗组合物定量 |
WO2014179200A1 (en) | 2013-04-30 | 2014-11-06 | Boehringer Ingelheim Vetmedica, Inc. | Orf2 protein of pcv2 subtype a (pcv2a) for use in cross-protection |
CN105658660A (zh) | 2013-10-02 | 2016-06-08 | 勃林格殷格翰动物保健公司 | Pcv2 orf2蛋白变体和由其组成的病毒样颗粒 |
US10195374B2 (en) | 2014-05-07 | 2019-02-05 | Boehringer Ingelheim International Gmbh | Container, nebulizer and use |
US10555994B2 (en) * | 2015-03-30 | 2020-02-11 | Boehringer Ingelheim Animal Health USA Inc. | PCV2 ORF2 carrier platform |
-
2014
- 2014-10-02 CN CN201480054488.4A patent/CN105658660A/zh active Pending
- 2014-10-02 US US14/504,839 patent/US9505808B2/en active Active
- 2014-10-02 CA CA2924228A patent/CA2924228C/en active Active
- 2014-10-02 JP JP2016519871A patent/JP6778104B2/ja active Active
- 2014-10-02 DK DK14789683.1T patent/DK3052516T3/da active
- 2014-10-02 ES ES14789683T patent/ES2778425T3/es active Active
- 2014-10-02 AU AU2014329524A patent/AU2014329524B2/en active Active
- 2014-10-02 KR KR1020167011660A patent/KR102409183B1/ko active IP Right Grant
- 2014-10-02 EA EA201600305A patent/EA035265B1/ru not_active IP Right Cessation
- 2014-10-02 KR KR1020227019654A patent/KR20220083861A/ko not_active Application Discontinuation
- 2014-10-02 MX MX2016004063A patent/MX2016004063A/es active IP Right Grant
- 2014-10-02 EP EP14789683.1A patent/EP3052516B1/en active Active
- 2014-10-02 WO PCT/US2014/058793 patent/WO2015051099A1/en active Application Filing
-
2016
- 2016-10-17 US US15/295,053 patent/US10131696B2/en active Active
-
2018
- 2018-10-08 US US16/154,294 patent/US10961281B2/en active Active
-
2021
- 2021-03-29 US US17/215,636 patent/US11858963B2/en active Active
-
2023
- 2023-11-21 US US18/516,237 patent/US20240076321A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016534034A5 (ja) | ||
PH12020550706A1 (en) | Adeno-associated virus variant capsids and use for inhibiting angiogenesis | |
PH12020550094A1 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
PH12018502387A1 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
JP2016539946A5 (ja) | ||
JP2010227101A5 (ja) | ||
JP2009544318A5 (ja) | ||
RU2017113571A (ru) | Рекомбинантные вакцины от fmdv и их применение | |
MX2016004063A (es) | Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta. | |
JP2012115277A5 (ja) | ||
JP2016538885A5 (ja) | ||
MX2020000221A (es) | Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas. | |
JP2016506416A5 (ja) | ||
JP2014512171A5 (ja) | ||
IL276210B2 (en) | MERS-COV vaccine | |
JP2011511754A5 (ja) | ||
JP2019505567A5 (ja) | ||
JP2015186478A5 (ja) | ||
JP2016513115A5 (ja) | ||
JP2013543499A5 (ja) | ||
JP2017502662A5 (ja) | ||
FI3355915T3 (fi) | Koirien parvoviruksen (CPV) viruksen kaltaisten hiukkasten (VLP) rokotteet ja niiden käytöt | |
JP2019534709A5 (ja) | ||
EP2552490A4 (en) | INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF | |
JP2014519817A5 (ja) |